Thymosin Alpha-1: What the Research Shows About This Immune-Modulating Peptide

Thymosin alpha-1 is a small peptide that has attracted serious scientific attention for nearly five decades. Naturally produced by the thymus gland, it plays a central role in regulating immune function. Outside the United States, it is sold under the brand name Zadaxin and is approved in over 35 countries for conditions ranging from chronic hepatitis B to cancer support.

In the US, it remains unapproved by the FDA for any indication, though it has been nominated for inclusion on the 503A compounding bulks list and is the subject of ongoing regulatory review.

This article is a research overview, not clinical guidance. Thymosin alpha-1 is not FDA-approved in the United States. This content is provided for educational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before considering any peptide or supplement.

---

What Is Thymosin Alpha-1?

Thymosin alpha-1, also called thymalfasin (the generic name for the synthetic version), is a 28-amino-acid peptide first isolated from thymic tissue in the 1970s by Allan Goldstein and his team at the National Cancer Institute. It is derived from a larger precursor protein called prothymosin alpha, which is expressed throughout the body.

In its natural form, thymosin alpha-1 is secreted by thymic epithelial cells and plays a key role in the maturation and differentiation of T cells, the immune system's primary adaptive responders. Thymosin alpha-1 levels are measurable in the bloodstream, and research has documented a meaningful decline in these levels with age, paralleling the well-known reduction in thymic activity that begins after puberty.

The synthetic version, thymalfasin, is structurally identical to the naturally occurring peptide. It is administered by subcutaneous injection, typically at doses of 1.6 mg, and has been studied in protocols ranging from twice-weekly cycles to continuous low-dose regimens.

---

How It Works: The Immune Mechanism

Thymosin alpha-1 operates at the intersection of innate and adaptive immunity, which is one of the reasons researchers have found it useful across such a wide range of conditions.

The foundational mechanistic work was done by Luigina Romani and colleagues at the University of Perugia, Italy. A landmark 2004 study published in *Blood* established that thymosin alpha-1 activates dendritic cells, the immune system's key antigen-presenting cells, through toll-like receptor (TLR) signaling (PMID: [14982877](https://pubmed.ncbi.nlm.nih.gov/14982877/)). Specifically, the peptide signals through the MyD88-dependent pathway to activate the p38 MAP kinase and NF-kappaB cascade, triggering production of interleukin-12 (IL-12), a cytokine that drives Th1 immune responses.

Th1 immunity is the branch of the adaptive immune system responsible for clearing intracellular pathogens (including viruses, certain bacteria, and fungi) as well as certain cancers. IL-12 production by dendritic cells is a critical early signal that instructs naive T cells to differentiate into Th1 effectors.

Beyond dendritic cells, thymosin alpha-1 also enhances natural killer (NK) cell activity and promotes the development of regulatory T cells (Tregs), which help prevent autoimmune overreaction. This dual role, stimulating pathogen-clearing and antitumor responses while also supporting immune balance, has made thymosin alpha-1 interesting to researchers studying both immunodeficiency states and excessive inflammation.

Enrico Garaci, a leading figure in thymosin alpha-1 research, summarized the compound's clinical translation potential in a 2007 review in the *Annals of the New York Academy of Sciences*, noting its "high potentiality" in combination approaches for viral and oncological disease (PMID: [17600290](https://pubmed.ncbi.nlm.nih.gov/17600290/)).

---

Clinical Evidence: Hepatitis B and C

The strongest body of clinical trial data for thymosin alpha-1 comes from hepatitis research.

Hepatitis B

A randomized controlled trial published in *Hepatology* in 1998 examined 98 patients with chronic hepatitis B. Researchers found that a 26-week course of thymosin alpha-1 produced a complete virological response rate of 40.6% at 18-month follow-up, compared to 9.4% in controls. Liver inflammation markers also improved in treated patients. The authors concluded it was effective and well-tolerated (PMID: [9581695](https://pubmed.ncbi.nlm.nih.gov/9581695/)).

Based on this and related trials, Zadaxin (thymalfasin) has received approval for chronic hepatitis B in several Asian and South American countries, including China, India, South Korea, and the Philippines.

Hepatitis C

The hepatitis C evidence is more mixed. A double-blind, placebo-controlled pilot trial published in *Liver* in 1996 found that thymosin alpha-1 monotherapy did not clear HCV-RNA in 19 patients over six months (PMID: [8873009](https://pubmed.ncbi.nlm.nih.gov/8873009/)). However, subsequent trials exploring combination therapy with interferon-alpha showed more promising results. A 1998 trial found that thymosin alpha-1 combined with interferon-alpha produced higher end-of-treatment virological response rates than interferon alone in patients with chronic hepatitis C (PMID: [9537454](https://pubmed.ncbi.nlm.nih.gov/9537454/)).

These findings suggested that thymosin alpha-1 may work best as an immune adjuvant, enhancing the effect of other therapies rather than acting as a standalone cure.

---

---

COVID-19: Mixed Evidence Worth Understanding

When SARS-CoV-2 emerged in 2020, thymosin alpha-1 became a subject of rapid clinical interest, particularly given its history as a registered treatment for viral infections in Asia.

Researchers at the University of Perugia, including Garaci and Puccetti, published a perspective in *Cell Death Discovery* in 2020 proposing that thymosin alpha-1 could modulate the pathogenic inflammation of COVID-19 at multiple stages of infection: boosting early antiviral immunity while simultaneously restraining the cytokine storm seen in severe cases (PMID: [32547788](https://pubmed.ncbi.nlm.nih.gov/32547788/)).

Clinical data that followed produced mixed results. A study published in *Clinical Infectious Diseases* in 2020 examined 76 severe COVID-19 patients in Wuhan and found that thymosin alpha-1 treatment was associated with significantly lower mortality compared to standard care alone: 11.1% versus 30.0% in patients with severe lymphocytopenia (PMID: [32442287](https://pubmed.ncbi.nlm.nih.gov/32442287/)). The researchers noted that patients with critically low T-cell counts appeared to benefit most.

A larger retrospective cohort study published in *Frontiers in Medicine* in 2021, covering 1,388 non-severe COVID-19 patients in Shanghai, found that thymosin alpha-1 shortened viral RNA shedding duration (13 vs. 16 days) and reduced hospital stays (14 vs. 18 days), though it did not significantly reduce mortality or disease progression in this less-severe population (PMID: [33968969](https://pubmed.ncbi.nlm.nih.gov/33968969/)).

It is important to read these results in context. The COVID-19 data is observational or retrospective in design, involves Asian patient populations receiving the drug in countries where it is routine clinical practice, and has not been replicated in large randomized controlled trials in Western populations. Broader meta-analyses of thymosin alpha-1 in COVID-19 have found inconsistent results across studies.

The honest summary: the data is suggestive but not definitive, and thymosin alpha-1 has not been approved for any COVID-19 indication anywhere.

---

The Longevity Angle: Thymic Aging and T-Cell Decline

Beyond its antiviral and anticancer applications, thymosin alpha-1 has attracted growing interest in the longevity and biohacking communities, primarily because of what happens to the thymus gland with age.

The thymus reaches peak activity during childhood and begins involuting after puberty. By middle age, the majority of thymic tissue has been replaced by fat. This structural decline correlates with reduced production of naive T cells, the immune system's fresh responders to new pathogens. Older adults have fewer naive T cells and a higher proportion of exhausted or senescent immune cells, which contributes to both reduced vaccine efficacy and increased susceptibility to infection.

Thymosin alpha-1 production also declines with age, suggesting a potential feedback loop: less thymic activity leads to lower thymosin alpha-1 levels, which further reduces T-cell maturation signals.

Whether supplementing thymosin alpha-1 in otherwise healthy older adults can meaningfully reverse or slow immunosenescence remains an open research question. Most of the existing clinical data comes from populations with specific immune deficiencies or active infections, not healthy longevity-focused adults. The mechanistic rationale is compelling, but longevity-specific clinical trials are not yet available.

For a broader look at how researchers are approaching the biology of aging, see the overview of [what peptide research reveals about longevity](/resources/science-of-longevity-what-peptide-research-reveals), and the article on [epitalon and telomere research](/resources/epitalon-longevity-peptide-research).

---

Current Regulatory Status in the United States

Thymosin alpha-1 (thymalfasin) is not approved by the FDA for any indication in the United States. This is a critical point for any patient or practitioner considering its use.

The compound has received orphan drug designation from the FDA for specific conditions including DiGeorge syndrome with immune defects, but orphan drug designation is not the same as market approval. Full approval was never achieved.

In December 2024, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed thymosin alpha-1 for potential inclusion on the 503A bulks list, which would clarify the legal pathway for licensed compounding pharmacies to prepare it for prescriptions. As of this writing, that review process is ongoing.

Outside the US, Zadaxin is approved in over 35 countries, primarily in Asia, South America, and parts of Eastern Europe. Approved indications vary by country but commonly include chronic hepatitis B, hepatocellular carcinoma, non-small cell lung cancer support, and malignant melanoma adjunct therapy.

Compounded thymosin alpha-1 is currently prepared by some 503A compounding pharmacies in the United States for patients with prescriptions from licensed providers. This is legal under current compounding regulations when a valid patient-specific prescription exists, but the regulatory landscape is subject to change.

---

Safety Profile

Thymosin alpha-1 has been administered in clinical trials involving thousands of patients over several decades, and its safety profile is generally considered favorable.

The most commonly reported adverse effects are mild injection site reactions: redness, swelling, and temporary discomfort at the subcutaneous injection site. These are generally self-limiting and resolve without intervention.

No serious systemic toxicity has been established at therapeutic doses in published trials. Thymosin alpha-1 does not appear to cause the broad immunosuppression or metabolic side effects associated with corticosteroids or other immunomodulatory drugs.

The most important theoretical caution involves patients with active autoimmune conditions. Because thymosin alpha-1 can enhance T-cell activation and Th1 immunity, there is a theoretical concern that it could exacerbate autoimmune disease in susceptible individuals. Clinical data on this question is limited. Practitioners typically advise caution or avoidance in patients with conditions like multiple sclerosis, lupus, or active inflammatory bowel disease.

---

Who Is Researching This and Why

Thymosin alpha-1 sits at an interesting intersection of immunology, infectious disease, oncology, and aging science. Its mechanism is well-characterized, its safety profile is reassuring, and there is a legitimate body of randomized controlled trial data in viral infection. That combination is unusual among peptides and has kept it in the research conversation.

The unanswered questions are real. Most trials have been conducted in Asian populations where the drug is already standard of care, which introduces selection and practice biases. Longevity-specific trials in healthy older adults have not been conducted. The optimal dosing protocol for different indications is still not fully defined.

For those interested in immune optimization as part of a broader longevity approach, thymosin alpha-1 is worth understanding and worth discussing with a provider who follows the research. It is not a proven treatment for any condition in the US, and it should be evaluated in the context of a complete medical history and immune workup.

See also: [NAD+ and Longevity Research](/resources/nad-plus-therapy-longevity) for related reading on how researchers are approaching cellular aging.

---

Disclaimer

*This article is for educational and research purposes only. Thymosin alpha-1 (thymalfasin) is not approved by the FDA for any indication in the United States. This content does not constitute medical advice, diagnosis, or a recommendation to use any specific compound. Compounded medications are not FDA-approved drugs. Individual results vary. Always consult a licensed healthcare provider before considering any peptide therapy or making changes to your health regimen. Clinical trial data cited in this article refers to studies conducted in specific populations under specific protocols and may not apply to your individual circumstances.*